Veronica Franchina
Overview
Explore the profile of Veronica Franchina including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
26
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stabile S, Testoni S, Franchina V, Betti M, Mannozzi F, Ferrari A, et al.
Rev Recent Clin Trials
. 2025 Jan;
PMID: 39886795
Background: Over the past decade, there has been a significant shift from paper-based to digital medical record management, driven largely by advances in digital technology. This transition has led to...
2.
Farina A, Medico P, Parisi S, Becciolini A, Visalli E, Molica-Colella A, et al.
Mediterr J Rheumatol
. 2025 Jan;
35(4):639-644.
PMID: 39886290
Background: Psoriatic arthritis (PsA) phenotypes show different responses to the many available drugs. For a tailored medicine, it is important to choose the most effective treatment according to patients' characteristics....
3.
Priora M, Becciolini A, Celletti E, Di Penta M, Lo Gullo A, Paroli M, et al.
Medicina (Kaunas)
. 2025 Jan;
60(12.
PMID: 39768862
The treatment landscape for Rheumatoid Arthritis (RA) has evolved significantly with the introduction of Janus kinase inhibitors (JAKi), such as Tofacitinib (TOFA), which offer a new therapeutic option for patients...
4.
Lo Gullo A, Parisi S, Becciolini A, Paroli M, Bravi E, Andracco R, et al.
Minerva Med
. 2024 Oct;
115(4):430-438.
PMID: 39376099
Background: Upadacitinib (UPA) is a selective, reversible Janus kinase inhibitor (JAKi) approved for the treatment of RA. However, there is still no solid evidence on the long-term efficacy of UPA...
5.
Paroli M, Becciolini A, Lo Gullo A, Parisi S, Bravi E, Andracco R, et al.
J Clin Med
. 2024 Jul;
13(13).
PMID: 38999494
The Janus kinase inhibitors (JAKi) tofacitinib (TOFA), baricitinib (BARI), upadacitinib (UPA), and filgotinib (FILGO) are effective drugs for the treatment of rheumatoid arthritis. However, the US Food and Drug Administration...
6.
Barbera L, Rizzo C, Camarda F, Atzeni F, Miceli G, Molica Colella A, et al.
Clin Exp Rheumatol
. 2024 Jan;
42(5):991-998.
PMID: 38197190
Objectives: We investigated the effectiveness and safety of filgotinib in a real-life multicentre cohort of rheumatoid arthritis (RA) patients. Methods: RA patients were evaluated at baseline and after 12 and...
7.
Paroli M, Becciolini A, Bravi E, Andracco R, Nucera V, Parisi S, et al.
Medicina (Kaunas)
. 2023 Aug;
59(8).
PMID: 37629770
: Tofacitinib (TOFA) was the first Janus kinase inhibitor (JAKi) to be approved for the treatment of rheumatoid arthritis (RA). However, data on the retention rate of TOFA therapy are...
8.
Lo Gullo A, Becciolini A, Parisi S, Medico P, Farina A, Visalli E, et al.
J Clin Med
. 2023 Jun;
12(12).
PMID: 37373587
Introduction: Enthesitis and dactylitis are difficult-to-treat features of psoriatic arthritis (PsA), leading to disability and affecting quality of life. Objective: The aim of this study is to evaluate enthesitis (using...
9.
Becciolini A, Parisi S, Medico P, Farina A, Visalli E, Molica Colella A, et al.
Biomedicines
. 2023 Feb;
11(2).
PMID: 36830969
Background: To date, only a few real-world-setting studies evaluated apremilast effectiveness in psoriatic arthritis (PsA). The aims of this retrospective observational study are to report long-term Disease Activity Index for...
10.
Ariani A, Parisi S, Medico P, Farina A, Visalli E, Molica Colella A, et al.
Clin Rheumatol
. 2022 Jul;
41(10):3219-3225.
PMID: 35796847
Objective: There are few real-world setting studies focused on apremilast effectiveness (i.e., retention rate) in psoriatic arthritis (PsA). The main aim of this retrospective observational study is the assessment of...